ANI Pharmaceuticals (ANIP) reported Q1 adjusted earnings Friday of $1.70 per diluted share, up from $1.21 a year earlier.
Analysts polled by FactSet expected $1.38.
Revenue for the quarter ended March 31 was $197.1 million compared with $137.4 million a year earlier.
Analysts surveyed by FactSet expected $180.6 million.
The company said it now expects 2025 adjusted EPS of $6.27 to $6.62 on revenue of $768 million to $793 million versus its prior outlook ranges of $6.12 to $6.49 and $756 million to $776 million, respectively.
The consensus is for $6.34 and $769.6 million, respectively.
ANI shares were up 3.5% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。